New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:08 EDTABAX, IDXX, VIVO, EXAS, QDEL, DGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
News For IDXX;DGX;EXAS;ABAX;QDEL;VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
19:32 EDTDGXQuest to acquire MemorialCare's laboratory outreach service business
Quest Diagnostics and MemorialCare Health System announced they have entered into a definitive agreement for Quest to acquire MemorialCare Health System's laboratory outreach service business. The transaction is expected to be neutral to earnings in 2015. Quest and MemorialCare Health System expect to complete the acquisition in August. Financial terms were not disclosed.
June 29, 2015
07:55 EDTIDXXZoetis could make a bid for IDEXX, says Canaccord
Canaccord hosted investor meetings with IDEXX (IDXX) management, who spoke about new product launches and their market share in light of competitive concerns. Management declined to comment on Zoetis' (ZTS) potential interest in scaling up its animal health diagnostics business, said Canaccord, which noted that it thinks Zoetis could make a bid for IDEXX. Canaccord reiterated its Buy rating and $80 price target on IDEXX shares, citing its cash on the balance sheet, low interest rates, recent CEO stock purchases and new product cycles that skew the risk/reward to the upside.
June 26, 2015
13:46 EDTEXASFly Watch: Exact Sciences predicted to jump if task force update favorable
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015. The guidelines should include an assessment of Exact Sciences' (EXAS) Cologuard, an "easy to use, noninvasive colon cancer screening test." ANALYST TAKE: The USPSTF guidelines were noted as "the last binary event for Cologuard" by Jefferies and "the major overhang" for Exact Sciences by Mizuho Securities. Jefferies analyst Brandon Couillard and his team, which rate Exact Sciences a Buy with a $33 price target, see "significant upside" from a favorable outcome and said their thesis was boosted by confident comments from a "former affiliate of the USPSTF's review board." Mizuho analysts Peter Lawson and Eric Criscuolo, who rate Exact Sciences a Buy with a $35 price target, said they believe Cologuard will receive an "A" or "B" rating from the USPSTF, triggering further adoption by mandating coverage of Cologuard by private insurance. Baird defended Exact Sciences after the stock dropped 5.5% on Thursday, June 25, saying Exact Sciences' investor relations day was "bullish" in tone as the company provided a "deep dive" update on its Cologuard launch. Baird maintained its Outperform rating and $44 price target on the company. PRICE ACTION: Over the past week, shares of Exact Sciences are up more than 5% despite Thursday's 5.5% pullback. Over the last month, shares are up about 12% and over the last three months they are higher by almost 40%.
08:18 EDTEXASExact Sciences recent weakness unwarranted, says Baird
Subscribe for More Information
07:17 EDTEXASExact Sciences compelling as a platform growth company, says Canaccord
Subscribe for More Information
June 25, 2015
08:03 EDTEXASExact Sciences to host analyst and investor day with a conference call hookup
Subscribe for More Information
06:34 EDTEXASExact Sciences' Cologuard shows strong sales in Q2
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use